Codexis to Announce Q4 Earnings on March 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CDXS?
Source: seekingalpha
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDXS
Wall Street analysts forecast CDXS stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.240
Low
2.00
Averages
6.00
High
11.00
Current: 1.240
Low
2.00
Averages
6.00
High
11.00
No data
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Codexis Reports 2025 Earnings, Significant Progress on ECOsynthesis Platform
- Market Potential: Codexis anticipates a $2 billion addressable market for production technologies in five years, driven by a 5% to 10% annual growth in siRNA drug development, positioning the company as a key technology provider in this space.
- Technical Milestone: In 2025, Codexis successfully synthesized 10 grams of commercially relevant siRNA, demonstrating the production capabilities of its ECOsynthesis platform without quality barriers, marking a significant advancement in biocatalytic enzyme innovation.
- Production Capacity Expansion: In 2026, Codexis has scaled production to 100 grams at its Eco Innovation Lab, with plans to reach half a kilo by year-end, further addressing customer demand for large-scale siRNA production.
- Strong Financial Performance: Codexis reported total revenues of $38.9 million for 2025, a significant increase from $21.5 million in 2024, primarily driven by a technology transfer agreement with Merck, with 2026 revenue expected to range between $72 million and $76 million.
See More
Codexis (CDXS) Q4 2025 Earnings Call Transcript
See More
Codexis Q4 Earnings Exceed Expectations
- Strong Performance: Codexis reported a Q4 GAAP EPS of $0.11, beating expectations by $0.14, indicating a significant improvement in profitability and enhancing its competitive position in the market.
- Revenue Surge: The company achieved Q4 revenue of $38.9 million, representing an 81.3% year-over-year increase and exceeding market expectations by $3.07 million, highlighting Codexis's robust business expansion and demand.
- Positive Outlook: Total revenues are projected to range between $72 million and $76 million for 2026, providing investor confidence and indicating the company's potential for sustained growth in the coming years.
- Sufficient Funding: Codexis expects that its existing cash, cash equivalents, and short-term investments will be adequate to fund planned operations through the end of 2027, demonstrating sound financial management and sustainability.
See More
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
Codexis Partners with Pharma Firm for siRNA Production
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
See More
Codexis Partners with Pharma Company for siRNA Manufacturing Agreement
- Agreement Signed: Codexis has entered into an agreement with an innovative pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, supporting preclinical development for a cardiovascular therapeutic candidate, marking a significant application of its technology for large-scale production.
- Technology Advantage: The ECO Synthesis platform is designed for efficient, scalable, and high-fidelity production of complex siRNA therapeutics, addressing the increasing manufacturing demands as RNA therapeutics transition from rare diseases to larger indications, showcasing Codexis's capability to meet evolving requirements.
- Market Opportunity Expansion: CEO Alison Moore highlighted that this partnership represents an important entry point into a high-volume market opportunity, illustrating the company's growth path as it continues to expand partnerships and position the platform for potential commercial-scale applications.
- Production Capacity Enhancement: With ECO Synthesis, Codexis can achieve efficient scale-up while maintaining product consistency, which is expected to drive growth in its market share within the RNAi therapeutics sector, meeting the rising manufacturing demands.
See More
Codexis Reports 2025 Earnings, Significant Progress on ECOsynthesis Platform
- Market Potential: Codexis anticipates a $2 billion addressable market for production technologies in five years, driven by a 5% to 10% annual growth in siRNA drug development, positioning the company as a key technology provider in this space.
- Technical Milestone: In 2025, Codexis successfully synthesized 10 grams of commercially relevant siRNA, demonstrating the production capabilities of its ECOsynthesis platform without quality barriers, marking a significant advancement in biocatalytic enzyme innovation.
- Production Capacity Expansion: In 2026, Codexis has scaled production to 100 grams at its Eco Innovation Lab, with plans to reach half a kilo by year-end, further addressing customer demand for large-scale siRNA production.
- Strong Financial Performance: Codexis reported total revenues of $38.9 million for 2025, a significant increase from $21.5 million in 2024, primarily driven by a technology transfer agreement with Merck, with 2026 revenue expected to range between $72 million and $76 million.
See More
Codexis (CDXS) Q4 2025 Earnings Call Transcript
See More
Codexis Q4 Earnings Exceed Expectations
- Strong Performance: Codexis reported a Q4 GAAP EPS of $0.11, beating expectations by $0.14, indicating a significant improvement in profitability and enhancing its competitive position in the market.
- Revenue Surge: The company achieved Q4 revenue of $38.9 million, representing an 81.3% year-over-year increase and exceeding market expectations by $3.07 million, highlighting Codexis's robust business expansion and demand.
- Positive Outlook: Total revenues are projected to range between $72 million and $76 million for 2026, providing investor confidence and indicating the company's potential for sustained growth in the coming years.
- Sufficient Funding: Codexis expects that its existing cash, cash equivalents, and short-term investments will be adequate to fund planned operations through the end of 2027, demonstrating sound financial management and sustainability.
See More
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
Codexis Partners with Pharma Firm for siRNA Production
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
See More
Codexis Partners with Pharma Company for siRNA Manufacturing Agreement
- Agreement Signed: Codexis has entered into an agreement with an innovative pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, supporting preclinical development for a cardiovascular therapeutic candidate, marking a significant application of its technology for large-scale production.
- Technology Advantage: The ECO Synthesis platform is designed for efficient, scalable, and high-fidelity production of complex siRNA therapeutics, addressing the increasing manufacturing demands as RNA therapeutics transition from rare diseases to larger indications, showcasing Codexis's capability to meet evolving requirements.
- Market Opportunity Expansion: CEO Alison Moore highlighted that this partnership represents an important entry point into a high-volume market opportunity, illustrating the company's growth path as it continues to expand partnerships and position the platform for potential commercial-scale applications.
- Production Capacity Enhancement: With ECO Synthesis, Codexis can achieve efficient scale-up while maintaining product consistency, which is expected to drive growth in its market share within the RNAi therapeutics sector, meeting the rising manufacturing demands.
See More
